Daniel L. Hartl

Daniel L. Hartl

Auto-generated profile, based on publicly available information

Daniel L. Hartl

Department of Organismic and Evolutionary Biology, Harvard University, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMichael Lynch
Michael Lynch
WSWay Sung
Way Sung
KMKrystalynne Morris
Krystalynne Morris
NCNicole Coffey
Nicole Coffey
CLChristian R. Landry
Christian R. Landry
WTW. Kelley Thomas
W. Kelley Thomas
The mutation process ultimately defines the genetic features of all populations and, hence, has a bearing on a wide range of issues involving evolutionary genetics, inheritance, and genetic disorders, including the predisposition to cancer. Nevertheless, formidable technical barriers have constrained our understanding of the rate at which mutations arise and the molecular spectrum of their effects. Here, we report on the use of complete-genome sequencing in the characterization of spontaneously arising mutations in the yeast Saccharomyces cerevisiae . Our results confirm some findings previously obtained by indirect methods but also yield numerous unexpected findings, in particular a very high rate of point mutation and skewed distribution of base-substitution types in the mitochondrion, a very high rate of segmental duplication and deletion in the nuclear genome, and substantial deviations in the mutational profile among various model organisms.

13 June 2003 in Science
Verified
Journal Article
Closed access
PDF file
JRJosé M. Ranz
José M. Ranz
CCCristian I. Castillo-Davis
Cristian I. Castillo-Davis
CMColin Meiklejohn
Colin Meiklejohn
DHDaniel L. Hartl
Daniel L. Hartl
Comparison of the gene-expression profiles between adults of Drosophila melanogaster and Drosophila simulans has uncovered the evolution of genes that exhibit sex-dependent regulation. Approximately half the genes showed differences in expression between the species, and among these, ∼83% involved a gain, loss, increase, decrease, or reversal of sex-biased expression. Most of the interspecific differences in messenger RNA abundance affect male-biased genes. Genes that differ in expression between the species showed functional clustering only if they were sex-biased. Our results suggest that sex-dependent selection may drive changes in expression of many of the most rapidly evolving genes in the Drosophila transcriptome.

27 December 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KGKerry A. Geiler-Samerotte
Kerry A. Geiler-Samerotte
MDMichael F. Dion
Michael F. Dion
BBBogdan A. Budnik
Bogdan A. Budnik
SWStephanie M. Wang
Stephanie M. Wang
DHDaniel L. Hartl
Daniel L. Hartl
DDD. Allan Drummond
D. Allan Drummond
Evolving lineages face a constant intracellular threat: most new coding sequence mutations destabilize the folding of the encoded protein. Misfolded proteins form insoluble aggregates and are hypothesized to be intrinsically cytotoxic. Here, we experimentally isolate a fitness cost caused by toxicity of misfolded proteins. We exclude other costs of protein misfolding, such as loss of functional protein or attenuation of growth-limiting protein synthesis resources, by comparing growth rates of budding yeast expressing folded or misfolded variants of a gratuitous protein, YFP, at equal levels. We quantify a fitness cost that increases with misfolded protein abundance, up to as much as a 3.2% growth rate reduction when misfolded YFP represents less than 0.1% of total cellular protein. Comparable experiments on variants of the yeast gene orotidine-5′-phosphate decarboxylase ( URA3 ) produce similar results. Quantitative proteomic measurements reveal that, within the cell, misfolded YFP induces coordinated synthesis of interacting cytosolic chaperone proteins in the absence of a wider stress response, providing evidence for an evolved modular response to misfolded proteins in the cytosol. These results underscore the distinct and evolutionarily relevant molecular threat of protein misfolding, independent of protein function. Assuming that most misfolded proteins impose similar costs, yeast cells express almost all proteins at steady-state levels sufficient to expose their encoding genes to selection against misfolding, lending credibility to the recent suggestion that such selection imposes a global constraint on molecular evolution.

21 July 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ELElena R. Lozovsky
Elena R. Lozovsky
TCThanat Chookajorn
Thanat Chookajorn
KBKyle M. Brown
Kyle M. Brown
MIMallika Imwong
Mallika Imwong
PSPhilip J. Shaw
Philip J. Shaw
DHDaniel L. Hartl
Daniel L. Hartl
The spread of high-level pyrimethamine resistance in Africa threatens to curtail the therapeutic lifetime of antifolate antimalarials. We studied the possible evolutionary pathways in the evolution of pyrimethamine resistance using an approach in which all possible mutational intermediates were created by site-directed mutagenesis and assayed for their level of drug resistance. The coding sequence for dihydrofolate reductase (DHFR) from the malaria parasite Plasmodium falciparum was mutagenized, and tests were carried out in Escherichia coli under conditions in which the endogenous bacterial enzyme was selectively inhibited. We studied 4 key amino acid replacements implicated in pyrimethamine resistance: N51I, C59R, S108N, and I164L. Using empirical estimates of the mutational spectrum in P. falciparum and probabilities of fixation based on the relative levels of resistance, we found that the predicted favored pathways of drug resistance are consistent with those reported in previous kinetic studies, as well as DHFR polymorphisms observed in natural populations. We found that 3 pathways account for nearly 90% of the simulated realizations of the evolution of pyrimethamine resistance. The most frequent pathway (S108N and then C59R, N51I, and I164L) accounts for more than half of the simulated realizations. Our results also suggest an explanation for why I164L is detected in Southeast Asia and South America, but not at significant frequencies in Africa.

16 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MHMatthew Hegreness
Matthew Hegreness
NSNoam Shoresh
Noam Shoresh
DDDoris Damian
Doris Damian
DHDaniel Hartl
Daniel Hartl
RKRoy Kishony
Roy Kishony
The emergence of resistance during multidrug chemotherapy impedes the treatment of many human diseases, including malaria, TB, HIV, and cancer. Although certain combination therapies have long been known to be more effective in curing patients than single drugs, the impact of such treatments on the evolution of drug resistance is unclear. In particular, very little is known about how the evolution of resistance is affected by the nature of the interactions—synergy or antagonism—between drugs. Here we directly measure the effect of various inhibitory and subinhibitory drug combinations on the rate of adaptation. We develop an automated assay for monitoring the parallel evolution of hundreds ofEscherchia colipopulations in a two-dimensional grid of drug gradients over many generations. We find a correlation between synergy and the rate of adaptation, whereby evolution in more synergistic drug combinations, typically preferred in clinical settings, is faster than evolution in antagonistic combinations. We also find that resistance to some synergistic combinations evolves faster than resistance to individual drugs. The accelerated evolution may be due to a larger selective advantage for resistance mutations in synergistic treatments. We describe a simple geometric model in which mutations conferring resistance to one drug of a synergistic pair prevent not only the inhibitory effect of that drug but also its enhancing effect on the other drug. Future study of the profound impact that synergy and other drug-pair properties can have on the rate of adaptation may suggest new treatment strategies for combating the spread of antibiotic resistance.

17 March 2006 in Science
Verified
Journal Article
Closed access
PDF file
MHMatthew Hegreness
Matthew Hegreness
NSNoam Shoresh
Noam Shoresh
DHDaniel Hartl
Daniel Hartl
RKRoy Kishony
Roy Kishony
Rapid evolution of asexual populations, such as that of cancer cells or of microorganisms developing drug resistance, can include the simultaneous spread of distinct beneficial mutations. We demonstrate that evolution in such cases is driven by the fitness effects and appearance times of only a small minority of favorable mutations. The complexity of the mutation-selection process is thereby greatly reduced, and much of the evolutionary dynamics can be encapsulated in two parameters—an effective selection coefficient and effective rate of beneficial mutations. We confirm this theoretical finding and estimate the effective parameters for evolving populations of fluorescently labeledEscherichia coli. The effective parameters constitute a simple description and provide a natural standard for comparing adaptation between species and across environments.